<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04384081</url>
  </required_header>
  <id_info>
    <org_study_id>1404-0021</org_study_id>
    <nct_id>NCT04384081</nct_id>
  </id_info>
  <brief_title>A Study to Test How Different Doses of BI 456906 Are Tolerated in Japanese Men With a Body Mass Index (BMI) Between 23 and 40 kg/m2</brief_title>
  <official_title>A Phase I, Single-blinded, Randomized, Multiple Dose, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Different Dose Escalation Schemes of BI 456906 in Healthy Japanese Male Subject With BMI 23-40 kg/m2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Main objectives are to investigate the safety, tolerability, pharmacokinetics and
      pharmacodynamics of different dose escalation schemes of BI 456906 in healthy Japanese male
      subject with BMI 23-40 kg/m2 and to determine a dose escalation scheme for future studies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative percentage (%) of subjects withdrawn from up-titration by dose escalation scheme.</measure>
    <time_frame>up to 113 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-168 (area under the concentration-time curve of BI 456906 in plasma over the time interval from 0 to 168h)</measure>
    <time_frame>up to 113 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum measured concentration of BI 456906 in plasma) after first dose</measure>
    <time_frame>up to 113 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dose group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 456906</intervention_name>
    <description>Solution for injection</description>
    <arm_group_label>Dose group 1</arm_group_label>
    <arm_group_label>Dose group 2</arm_group_label>
    <arm_group_label>Dose group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Solution for injection</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy males according to the assessment of the investigator, based on a complete
             medical history, a physical examination, vital signs (BP, PR), 12-lead ECG, and
             clinical laboratory tests at screening visit

          2. Japanese ethnicity, according to the following criteria:

             - born in Japan, have lived outside of Japan &lt;10 years, and have parents and
             grandparents who are Japanese

          3. Age of 20 to 45 years (inclusive) at screening visit.

          4. BMI of 23.0 to 40.0 kg/m2 (inclusive) with a minimum absolute body weight of 65 kg at
             screening visit and a stable body weight (defined as no more than 5% change) 3 months
             prior to screening visit.

          5. Signed and dated written informed consent in accordance with ICH-GCP and local
             legislation prior to admission to the trial

          6. Subjects who agree to minimize the risk of making their partner pregnant by fulfilling
             any of the following criteria starting from the first administration of trial
             medication until 90 days after last administration of trial medication

               -  Use of adequate contraception, any of the following methods plus condom:
                  intrauterine device, combined oral contraceptives that started at least 2 months
                  prior to the first drug administration.

               -  Vasectomized (vasectomy at least 1 year prior to enrolment)

               -  Surgical sterilization (including bilateral tubal occlusion, hysterectomy or
                  bilateral oophorectomy) of the subjects female partner

          7. HbA1c &lt; 6.5% at screening visit

        Exclusion Criteria:

          1. Exposure to any glucagon-like peptide 1 receptor (GLP-1R) agonist (including
             combination products) within twelve months prior to screening visit, or any previous
             exposure to BI 456906, or history of relevant allergy or hypersensitivity (including
             allergy, intolerability or lack of efficacy to trial medication or drugs that belong
             to the GLP-1R agonist class)

          2. Major surgery (major according to the investigator's assessment) performed within 12
             weeks prior to randomization or planned within 6 months after screening visit, e.g.
             hip replacement

          3. Any evidence of a concomitant disease, baseline condition, or medical history assessed
             as clinically relevant by the investigator including:

               -  Repeated measurement of supine blood pressure (BP) ≥160/95 mmHg, or pulse rate
                  (PR) &gt;90 bpm after 5 minutes of resting at screening visit.

               -  Renal artery stenosis or evidence of labile blood pressure including symptomatic
                  hypotension, or history of relevant orthostatic hypotension, fainting spells, or
                  blackouts.

               -  A marked baseline prolongation of Q wave to T wave (QT)/QTc (corrected) interval
                  (such as QTc intervals that are greater than 450 ms at screening or an increase
                  of 30 ms versus screening or any other relevant ECG finding at screening (e.g.,
                  type 2 second-degree atrioventricular (AV) block (Type Mobitz II) or third-degree
                  AV block) and heart rhythm disturbances (e.g., bradycardia with baseline heart
                  rate (HR) &lt;45 bpm (in the absence of medications that lower the heart rate), or
                  tachyarrhythmia or ventricular tachycardia).

               -  Family history of long QT-syndrome, use of prescription or over-the-counter
                  medications known to significantly prolong the QT or QTc interval at screening.

               -  A history of pancreatitis or a history of/current increase of Amylase/Lipase &gt;
                  1.5- fold Upper limit of normal (ULN)

               -  Any documented active or suspected malignancy or history of malignancy within 5
                  years prior to screening visit, except appropriately treated basal cell carcinoma
                  of the skin, personal or family history of medullary thyroid carcinoma or history
                  of multiple endocrine neoplasia syndrome type 2

               -  Any clinical condition that requires continuous pharmacotherapy during the trial.
                  Pharmacotherapy that potentially induce a change in body weight (for example
                  anti-hyperglycemic, anti-depressant, diuretics, steroids, insulin,
                  anti-psychotics) need to be stopped 6 months prior to screening visit

               -  Cholecystectomy and/or prior surgery of the GI tract (including bariatric
                  surgery) that could interfere with body weight or the pharmacokinetics (PK) of
                  the trial medication or auxiliary medicinal products of the trial [paracetamol
                  (acetaminophen)] except appendectomy and simple hernia repair.

               -  Diseases of the central nervous system (including but not limited to any kind of
                  seizures or stroke), and other relevant neurological or psychiatric disorders

               -  Chronic or relevant acute infections including viral hepatitis, human
                  immunodeficiency virus (HIV) and/or syphilis.

               -  History of relevant allergy or hypersensitivity (including allergy to trial
                  medication or its excipients)

               -  History of congestive heart failure New York Heart Association (NYHA) class IIIV
                  or cardiovascular abnormalities such as ventricular or supraventricular
                  arrhythmias. History of symptomatic ventricular tachycardia, or history of type 2
                  second-degree AV block (Type Mobitz II) or third-degree AV block.

               -  Any of the following conditions or procedures within the last six months prior to
                  screening: myocardial infarction, unstable angina, coronary artery bypass graft
                  (e.g. carotid bypass, peripheral vascular diseases bypass), percutaneous coronary
                  intervention (diagnostic angiograms are permitted), transient ischaemic attack,
                  cerebrovascular accident (stroke) or decompensated congestive heart failure.

               -  Any lifetime history of suicidal behavior (i.e. actual attempt, interrupted
                  attempt, aborted attempt, or preparatory acts or behavior).

               -  Any suicidal ideation of type 2 to 5 on the Columbia-Suicide Severity Rating
                  Scale (C-SSRS) in the past 12 months (i.e. active suicidal thought without
                  method, intent or plan; active suicidal thought with method but without intent or
                  plan; active suicidal thought with method and intent but without specific plan;
                  or active suicidal thought with method, intent and plan).

          4. Use of drugs within 30 days prior to administration of trial medication if that might
             reasonably influence the results of the trial (including drugs that cause QT/QTc
             interval prolongation)

          5. Participation in another trial where an investigational drug has been administered
             within 60 days or 5 half-lives (whichever is longer) prior to planned administration
             of trial medication, or current participation in another trial involving
             administration of investigational drug

          6. Current smokers (defined as more than 10 cigarettes or 3 cigars or 3 pipes per day)

          7. Inability to refrain from smoking on specified trial days

          8. Alcohol abuse (consumption of more than 24 g per day) Further exclusion criteria apply
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>SOUSEIKAI Sumida Hospital</name>
      <address>
        <city>Tokyo, Sumida-ku</city>
        <zip>130-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rie Yazawa</last_name>
      <phone>+81 3 56087276</phone>
      <email>rie-yazawa@lta-med.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 11, 2020</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non‐interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:
studies in products where Boehringer Ingelheim is not the license holder;
studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;
studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).
For more details refer to: http://trials.boehringer-ingelheim.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

